

Effective as of 12/01/2025

Additional ordering and billing information

Information when ordering laboratory tests that are billed to Medicare/Medicaid

<u>Information regarding Current Procedural Terminology (CPT)</u>

Test Number	Mnemonic	Test Name	New Test	Test Name Change	Specimen Requirements	Methodology	Note	Interpretive Data	Reference Interval	Component Charting Name	Component Change	Reflex Pattern	Result Type	Ask at Order Prompt	Numeric Map	Unit of Measure	CPT Code	Pricing Change	Inactivation w/ Replacement	Inactivation w/o Replacement
0054441	MEASLMCSF	Measles (Rubeola) Antibody, IgM, CSF by IFA		x	x	x		x	X											
2007580	HEP CO 2	Heparin Cofactor																		x
2014059	4KSCORE	Prostate-Specific Kallikrein, 4Kscore			х		х				х									
2014277	CARBAR PCR	Antimicrobial Susceptibility - Carbapenemase Gene Detection by PCR					x				x									
3002309	OVA1 PLUS	Malignancy Risk Assessment, Pelvic Mass, OVA1 Plus			x	x	x													
3005941	HISTO GAL	Histoplasma Galactomannan Antigen by EIA, Quantitative, Other Body Fluids			x															
3017752	ENCEPH-CSF	Encephalitis Panel With Reflex to Herpes Simplex Virus Types 1 and 2 Glycoprotein G- Specific Antibodies, IgG, CSF		x		x		x	x											
3018823	AT1R	Anti-Angiotensin Type 1 Receptor (AT1R)					x													





Effective as of 12/01/2025

Additional ordering and billing information

Information when ordering laboratory tests that are billed to Medicare/Medicaid

<u>Information regarding Current Procedural Terminology (CPT)</u>

Test Number	Mnemonic	Test Name	New Test	Test Name Change	Specimen Requirements	Methodology	Note	Interpretive Data	Reference Interval	Component Charting Name	Component Change	Reflex Pattern	Result Type	Ask at Order Prompt	Numeric Map	Unit of Measure	CPT Code	Pricing Change	Inactivation w/ Replacement	Inactivation w/o Replacement
3019850	GHRELIN	Ghrelin, Total				Х											Х			
3020479	IMATINIB S	Imatinib, Serum	х																	



TEST CHANGE

Measles (Rubeola) Antibody, IgM, CSF by IFA

0054441, MEASLMCSF

Specimen Requirements:

Patient Preparation:

CSF. Collect:

Specimen Preparation: Transfer 0.5 mL CSF to an ARUP standard transport

> tube. Standard Transport Tube. (Min: 0.2 mL) New York State Clients: 1 mL (Min: 0.075 mL)

Transport Temperature: Refrigerated. Also acceptable: Frozen.

New York State Clients: Refrigerated

Unacceptable Conditions: Bacterially contaminated, heat-inactivated, hemolyzed, or

xanthochromic specimens.

Remarks:

Stability: Ambient: 488 hours; Refrigerated: 2 weeks; Frozen: 1

monthyear

New York State Clients: Ambient: 1 week; Refrigerated: 2

weeks; Frozen: 1 month

Methodology: Semi-Quantitative Indirect Fluorescent Antibody (IFA Enzyme-

Linked Immunosorbent Assay (ELISA)

Note:

CPT Codes: 86765

New York DOH Approval Status: Specimens from New York clients will be sent out to a New

York DOH approved laboratory, if possible.

Interpretive Data:

The detection of antibodies to rubeola in CSF may indicate central nervous system infection. However, consideration must be given to possible contamination by blood or transfer of serum antibodies across the blood-brain barrier.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Less than 1:20.79 AU or less

evidence of recent infection. Falsenegative results are possible if the specimen was collected too soon <u>after</u> exposure. Negative - No significant level of IgM antibodies to measles (rubeola) virus detected.

Negative: No



0.80-1.20 AU	Equivocal - Repeat testing in 10-14 days may be helpful.
1:2-21 AU or greater	Positive: Indicative of recent primary measles infection. Positive - IgM antibodies to measles (rubeola) virus detected. Suggestive of current or recent infection or immunization. However, low levels of IgM antibodies may occasionally persist for more than 12 months post-infection or immunization.

Reference Interval:

Test Number	Components	Reference Interval
	Measles, Rubeola, Antibody IgM CSF	Less than 1:20.79 AU or less



TEST CHANGE

Prostate-Specific Kallikrein, 4Kscore

2014059, 4KSCORE

2014059, 4KSCORE	
Specimen Requirements:	
Patient Preparation:	
Collect:	Serum separator tube (SST).
Specimen Preparation:	Transfer 4 mL serum to an ARUP standard transport tube. (Min: 3 mL) Test is not performed at ARUP; separate specimens must be submitted when multiple tests are ordered.
Transport Temperature:	Frozen.
Unacceptable Conditions:	Frozen serum separator tubes (SST).
Remarks:	Biopsy history, <u>digital rectal exam (DRE) results</u> , and clinical indication for ordering are required. <u>Digital Rectal Exam (DRE) result should be provided</u> , if available.
Stability:	Ambient: Unacceptable; Refrigerated: 72 hours; Frozen: 1 month
Methodology:	Electrochemiluminescent Immunoassay (ECLIA)
Note:	4 Kallikrein Biomarkers: Total PSA, free PSA, percent free PSA, intact PSA, and hK2. <u>Digital Rectal ExamA digital rectal exam</u> (DRE) <u>resultis required and submissions</u> should indicate " <u>abnormal"</u> , " <u>normal"</u> , <u>nodule"</u> or " <u>unavailable"</u> . <u>no nodule."</u> Test should not be ordered if DRE has been performed within the last 4 days or if biopsy history is positive. DREs performed after collection of specimen are acceptable.
CPT Codes:	81539
New York DOH Approval Status:	This test is New York DOH approved.
Interpretive Data:	
Reference Interval:	
By report	

Effective Date: December 1, 2025

HOTLINE NOTE: There is a component change associated with this test. One or more components have been added or removed. Refer to the Hotline Test Mix for interface build information.

TEST CHANGE

Antimicrobial Susceptibility - Carbapenemase Gene Detection by PCR 2014277, CARBAR PCR

Specimen Requirements:				
Patient Preparation:				
Collect:	Actively growing Enterobacteriaceae, Pseudomonas aeruginosa, or Acinetobacter baumannii in pure culture.			
Specimen Preparation:	Transport sealed container with pure culture on agar slant/bacterial transport media. Place each specimen in an individually sealed bag.			
Transport Temperature:	Room temperature.			
Unacceptable Conditions:	Mixed cultures or nonviable organisms.			
Remarks:	Isolate identification (for cultures) and specimen source required.			
Stability:	Ambient: 1 week; Refrigerated: 1 week; Frozen: Unacceptable			
Methodology:	Qualitative Polymerase Chain Reaction (PCR)			
Note:	An additional processing fee will be billed for all isolates not submitted in pure culture, as indicated in the specimen requirements.			
	If species identification is not provided, identification will be performed at ARUP. Additional charges apply.			
	The blaIMP family is highly diverse and many variants that diverge from the IMP-1 sequence may not be detected. This assay will generate a negative IMP result when testing samples containing IMP-2, IMP-7, IMP-8, IMP-13, or IMP-14 gene sequences, and may detect IMP-4 at reduced sensitivity. This assay may also generate a false-negative result for uncommon OXA-48-like variants.			
CPT Codes:	87150			
New York DOH Approval Status:	This test is New York DOH approved.			
Interpretive Data:				
This assay detects five carbapenemase gene families (blaKPC, blaNDM, blaOXA-48, blaVIM, blaIMP) encoding enzymes that may confer resistance to carbapenem and other beta-lactam antibiotics. This assay is intended for use as an aid to infection control in the detection of carbapenem-resistant bacteria and is not intended to guide or monitor treatment of infection. A				

Reference Interval:

Not Detected

Deleted Cells

specific nucleic acid in concentrations below the level of detection.

negative result does not exclude the presence of other resistance mechanisms or assay-



HOTLINE NOTE: There is a component change associated with this test. One or more components have been added or removed. Refer to the Hotline Test Mix for interface build information.

TEST CHANGE

Malignancy Risk Assessment, Pelvic Mass, OVA1 Plus 3002309, OVA1 PLUS

0002003, 017.11 1 200	
Specimen Requirements:	
Patient Preparation:	Testing should not be performed on patients 17 years of age or younger.
Collect:	Serum <u>separator tube</u> Separator Tube (SST).
Specimen Preparation:	Transfer 2.2 mL serum to an ARUP <u>standard transport</u> <u>tube</u> .Standard Transport Tube. (Min: 1.1 mL)
Transport Temperature:	Frozen. Also acceptable: Refrigerated.
Unacceptable Conditions:	
Remarks:	Menopausal <u>s</u> Status required at time of ordering.
Stability:	Ambient: Unacceptable; Refrigerated: 8 days; Frozen: 9 weeks
Methodology:	Electrochemiluminescent Immunoassay (ECLIA) / Fixed-Rate-Time Nephelometry
Note:	OVA1 Biomarkers: CA-125 II, <u>a</u> Apoliproprotein A1 (Apo A-1), <u>b</u> Beta-2 <u>m</u> Microglobulin (B2M), <u>t</u> Transferrin, and <u>p</u> Prealbumin.
	OVERA Biomarkers: Apolipoprotein A1 (Apo A-1), HE4 (human epididymisHuman Epididymis protein 4), CA-125 II, FSH (follicle stimulating hormone Follicle Stimulating Hormone), and taransferrin.
CPT Codes:	81503
New York DOH Approval Status:	This test is New York DOH approved.
Interpretive Data:	
Reference Interval:	
By Report	

Deleted Cells



TEST CHANGE

Histoplasma Galactomannan Antigen by EIA, Quantitative, Other Body Fluids 3005941, HISTO GAL

· · · · · · · · · · · · · · ·	
Specimen Requirements:	
Patient Preparation:	
Collect:	Lavender (K2 or K3EDTA), green (sodium or lithium heparin), light blue (sodium citrate). Also acceptable: BAL or CSF.
Specimen Preparation:	Transfer 2 mL plasma to an ARUP standard transport tube. (Min: 1.2 mL) Transfer 1 mL BAL to an ARUP standard transport tube. (Min: 0.5 mL) Transfer 1 mL CSF to an ARUP standard transport tube. (Min: 0.8 mL) Test is not performed at ARUP; separate specimens must be submitted when multiple tests are ordered.
Transport Temperature:	<u>FrozenRefrigerated</u> . Also acceptable: Room temperature or <u>refrigerated</u> frozen.
Unacceptable Conditions:	
Remarks:	
Stability:	Ambient: 2 weeks; Refrigerated: 2 weeks; Frozen: Indefinitely
Methodology:	Quantitative Enzyme-Linked Immunosorbent Assay (ELISA)
Note:	For serum specimens refer to Histoplasma Antigen Quantitative by EIA, Serum (ARUP test code 0092522).
CPT Codes:	87385
New York DOH Approval Status:	This test is New York DOH approved.
Interpretive Data:	
Reference Interval:	
By report	



ABORATORIES

TEST CHANGE

Encephalitis Panel With Reflex to Herpes Simplex Virus Types 1 and 2 Glycoprotein G-Specific Antibodies, IgG, CSF

3017752, ENCEPH-CSF

Specimen Requirements:	
Patient Preparation:	
Collect:	CSF.
0 ' D ''	T (50 1005) ABUB : 1 1: (4)

Specimen Preparation: Transfer 5.0mL CSF to an ARUP standard transport tube. (Min: 2.5mL)

Transport Temperature: Refrigerated.

Unacceptable Conditions: Serum or plasma. Contaminated, heat-inactivated, or

hemolyzed specimens.

Remarks:

Stability: Ambient: 8 hours; Refrigerated: 2 weeks; Frozen: 1 month

Methodology: Semi-Quantitative Enzyme-Linked Immunosorbent Assay

(ELISA) / Semi-Quantitative Chemiluminescent Immunoassay (CLIA) / Semi-Quantitative Indirect Fluorescent Antibody (IFA)

Effective Date: December 1, 2025

Note: If HSV 1 and/or 2 IgG, CSF is 1.10 IV or greater, then HSV 1 G-

specific IgG, CSF and HSV 2 G-specific IgG, CSF will be added.

Additional charges apply.

CPT Codes: 86765 x2; 86735 x2; 86787 x2; 86789; 86788; 86694; if

reflexed, add 86695; 86696

New York DOH Approval Status: Specimens from New York clients will be sent out to a New

York DOH approved laboratory, if possible.

Interpretive Data:

Measles

Component Interpretation Measles 13.4 AU/mL or (Rubeola) less: Negative. No Antibody, IgG, significant level of IaG antibody to **CSF** measles (rubeola) virus detected. 13.5-16.4 AU/mL: Equivocal. Repeat testing in 10-14 days may be helpful. 16.5 AU/mL or greater: Positive. IgG antibody to measles (rubeola) detected, which may indicate a current or past

measles (rubeola) infection.

Less than 1:2:

ARUP Laboratories | 500 Chipeta Way | Salt Lake City, UT 84108 | 800-522-2787 | aruplab.com



(Rubeola) Antibody, IgM, CSF<u>by IFA</u> Negative. No evidence of recent infection. False-negative results are possible if the specimen was collected too soon after exposure. 1:2 or greater: Positive. **Indicative of** recent primary measles infection. 0.79 AU or less: Negative. No significant level of IgM antibodies to measles (rubeola) virus detected. 0.80-1.20 AU: Equivocal. Repeat testing in 10-14 days may be helpful. 1.21 AU or greater: Positive. IgM antibodies to measles (rubeola) virus detected. Suggestive of current or recent infection or immunization. However, low levels of IgM antibodies may occasionally persist for more than 12 months post infection or immunization.

Mumps Virus 8.9 AU/mL or Antibody IgG, CSF less: Negative. No

8.9 AU/mL or significant level of detectable IgG mumps virus antibody. 9.0-10.9 AU/mL: Equivocal. Repeat testing in 10-14 days may be helpful. 11.0 AU/mL or greater: Positive. IgG antibody to mumps virus detected, which may indicate a current or past



Mumps Virus Antibody IgM, CSF mumps virus infection.

0.79 IV or less: Negative. No significant level of detectable IgM antibody to mumps virus. 0.80-1.20 IV: Equivocal. Borderline levels of IgM antibody to mumps virus. Repeat testing in 10-14 days may be helpful. 1.21 IV or greater: Positive. Presence of IgM antibody to mumps virus detected, which may indicate a current or recent infection. However, low levels of IgM antibody may occasionally persist for more than 12 months post infection or

Varicella-Zoster Virus Antibody, IgG, CSF Less than or equal to ←0.99 S/CO: Negative: No significant level of IgG antibody to varicella-zoster virus detected. Greater than or equal to >= 1.00 S/CO: Positive:-IgG antibody to varicella-zoster virus detected, which may indicate a current or past varicellazoster infection. 0.90 ISR or less:

immunization.

Varicella-Zoster Virus Antibody, IgM by ELISA (CSF)

Negative. No significant level of IgM antibody to varicella-zoster virus detected. 0.91-1.09 ISR: Equivocal. Repeat testing in 10-14

days may be helpful. 1.10 ISR or greater: Positive. Significant level of IgM antibody to varicella-zoster virus detected, which may indicate current or recent infection. However, low levels of IgM antibodies may occasionally persist for more than 12 months post infection. 0.89 IV or less: Negative. No significant level IgG antibody. 0.90-1.09 IV:

Herpes Simplex Virus Type 1 and/or 2 Antibodies, IgG, CSF

of detectable HSV Equivocal. Questionable presence of IgG antibodies. Repeat testing in 10-14 days may be helpful. 1.10 IV or greater: Positive. IgG antibody to HSV detected which may indicate a current or past HSV infection. 1.29 IV or less: Negative. No

West Nile Virus Antibody, IgG by ELISA, CSF

significant level of West Nile virus IgG antibody detected, 1.30-1.49 IV: Equivocal. Questionable presence of West Nile virus IgG antibody detected. Repeat testing in 10-14 days may be helpful. 1.50 IV or greater: Positive. Presence of IgG antibody to West Nile virus detected,



suggestive of current or past infection. 0.89 IV or less: West Nile Virus Antibody, IgM by Negative. No ELISA, CSF significant level of West Nile virus IgM antibody detected. 0.90-1.10 IV: Equivocal. Questionable presence of West Nile virus IgM antibody detected. Repeat testing in 10-14 days may be helpful. 1.11 IV or greater: Positive. Presence of IgM antibody to West Nile virus detected,

Effective Date: December 1, 2025

Reference Interval:

suggestive of current or recent infection.

Test Number	Components Reference Interval					
	HSV 1/2 Antibody Screen IgG, CSF	0.89 IV or les	s			
	Measles, Rubeola, Antibody IgG CSF	16.4 AU/mL	or less			
	Measles, Rubeola, Antibody IgM CSF	Less than 1:2	2 <mark>0.79 AU or less</mark>			
	Mumps Virus Antibody IgG CSF	10.9 AU/mL	or less			
	Mumps Virus Antibody IgM CSF	0.79 IV or les	s			
	VZV Antibody IgG CSF	0.99 S/CO or	<u>less</u>			
		<=0.99 S/CO	Negative - No significant level of IgG antibody to varicella-zoster virus detected.			
		>=1.00 S/CO	Positive - IgG antibody to varicella-zoster virus detected, which may indicate a current or past varicella- zoster infection.			
	VZV Antibody IgM CSF	0.90 ISR or le	ess			
	West Nile Virus Antibody IgG CSF	1.29 IV or les	s			
	West Nile Virus Antibody IgM CSF	0.89 IV or les	0.89 IV or less			





TEST CHANGE

Anti-Angiotensin Type 1 Receptor (AT1R)

3018823, AT1R

Specimen Requirements:	
Patient Preparation:	Collect specimen prior to hemodialysis.
Collect:	Plain red.
Specimen Preparation:	Transfer 3 mL serum to an ARUP standard transport tube. (Min: 0.5) Test is not performed at ARUP; separate specimens must be submitted when multiple tests are ordered.
Transport Temperature:	Frozen. Also acceptable: Refrigerated
Unacceptable Conditions:	
Remarks:	
Stability:	Ambient: Unacceptable; Refrigerated: 1 week; Frozen: 6 months
Methodology:	Enzyme-Linked Immunosorbent Assay (ELISA)
Note:	Order must indicate transplant type and whether the specimen is pre- or post-transplant.
CPT Codes:	86316
New York DOH Approval Status:	This test is New York DOH approved.
Interpretive Data:	
Reference Interval:	



TEST CHANGE

Ghrelin, Total 3019850, GHRELIN

Specimen Requirements:	
Patient Preparation:	Fast 10-12 hours prior to specimen collection. Discontinue any medications or supplements that may influence cholecystokinin (CCK), glucose, growth hormone, insulin, or somatostatin levels, if possible, for 48 hours prior to collection.
Collect:	GI preservative tube (ARUP supply #47531). Available online through eSupply using ARUP Connect(TM) or contact ARUP Client Services at 800-522-2787.
Specimen Preparation:	Separate from cells ASAP. Transfer 5 mL plasma to ARUP standard transport tubes and freeze immediately. (Min: 1 mL) Test is not performed at ARUP; separate specimens must be submitted when multiple tests are ordered.
Transport Temperature:	CRITICAL FROZEN.
Unacceptable Conditions:	
Remarks:	
Stability:	Ambient: Unacceptable; Refrigerated: 24 hours; Frozen: 6 months
Methodology:	Quantitative Radioimmunoassay (RIA Enzyme-Linked Immunosorbent Assay (ELISA)
Note:	
CPT Codes:	835 <u>19</u> 20
New York DOH Approval Status:	Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Interpretive Data:	
Reference Interval:	
By report	



NEW TEST

Click for Pricing

Imatinib, Serum

3020479, IMATINIB S

Reference Interval:

Refer to report

Specimen Requirements:	
Patient Preparation:	
Collect:	Plain red
Specimen Preparation:	Transfer 1 mL serum to an ARUP standard transport tube. (Min: 0.2 mL) Test is not performed at ARUP; separate specimens must be submitted when multiple tests are ordered.
Transport Temperature:	Frozen. Also acceptable: Room temperature or refrigerated.
Unacceptable Conditions:	
Remarks:	
Stability:	Ambient: 5 days; Refrigerated: 5 days; Frozen: 1 year
Methodology:	Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Note:	
CPT Codes:	80299
New York DOH Approval Status:	This test is New York DOH approved.
Interpretive Data:	

Effective Date: December 1, 2025

HOTLINE NOTE: Refer to the Hotline Test Mix for interface build information.



Inactivations

The following will be discontinued from ARUP's test menu on December 1, 2025 Replacement test options are indicated when applicable.

Test Number	Test Name	Refer to Replacement Test
2007580	Heparin Cofactor II	